ReviewJACC. Asia2026
Drivers of Atherosclerotic Cardiovascular Disease in South Asians: Current Insights and Future Directions.
Review in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Disparities in Breast Cancer Diagnosis, Treatment, and Outcomes Among South Asian American Women.Cancers · 2026Article
- South Asian Cardiovascular Risk: Role of Coronary Artery Calcium Scoring and Computed Tomography Angiography.JACC. Asia · 2026Review
- Advancing Cardiovascular Disease Prevention in Asian Populations.JACC. Asia · 2026Article
- Combined assessment of carotid intima-media thickness and epicardial fat thickness for cardiovascular risk stratification in asymptomatic South Indian adults.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality, with South Asians experiencing a disproportionately high burden. This excess risk is not fully explained by conventional risk factors, highlighting the need for a more nuanced understanding. However, progress has been hindered by a paucity of South Asian-specific research, limited validation studies, and under-representation in clinical trials. Emerging evidence points to a complex interplay of genetic predisposition, cardiometabolic dysfunction, lifestyle, and socioeconomic influences driving this heightened susceptibility. This review synthesizes recent advancements in genomics, lipid metabolism, biomarkers, imaging, and composite risk calculators, aiming to refine risk stratification in clinical practice. Additionally, we discuss key limitations in current research and explore future directions to bridge knowledge gaps. A deeper understanding of these factors is essential to developing targeted interventions and identifying novel therapeutic strategies to attenuate the elevated atherosclerotic cardiovascular disease risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.